Rituximab for the treatment of the skin manifestations of dermatomyositis: A report of 3 cases

Dinh, Hope; McCormack, Christopher; Hall, Stephen; Prince, H. Miles

doi:10.1016/j.jaad.2006.05.068

Cited by 77 publications

(61 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…RTX has also demonstrated efficacy in patients with DM with improvement of both muscle and skin disease [56,57], although other studies reported limited response in patients with refractory skin involvement [58,59]. Beneficial effects of RTX have been described in patients with juvenile DM [60,61] and with anti-synthetase syndrome (ASS) [62,63].…”

Section: Biologic Therapymentioning

confidence: 99%

Current pharmacological treatment of idiopathic inflammatory myopathies

Fasano

Alves²,

Isenberg

2016

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

The idiopathic inflammatory myopathies are uncommon and heterogeneous disorders. Their classification is based on distinct clinicopathologic features. Although idiopathic inflammatory myopathies share some similarities, different subtypes may have variable responses to therapy, so it is very important to distinguish the correct subtype.There are few randomised, double blind placebo controlled studies to support the current treatment.High dose corticosteroids continue to be the first line therapy and other immunosupressive drugs are used in refractory cases, as well as steroid-sparing agents.Some novel therapeutic approaches have emerged as potential treatment including tacrolimus, intravenous immunoglobulin and rituximab, following good outcomes reported in case studies.However, more randomised controlled trials are needed.This review considers the current and the potential future therapies for inflammatory myopathies.

show abstract

Section: Biologic Therapymentioning

confidence: 99%

Current pharmacological treatment of idiopathic inflammatory myopathies

Fasano

Alves²,

Isenberg

2016

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

show abstract

“…Kompleman kaskadı aktivasyonundan sonra, bu antikorlar inflamatuvar medyatör salınımına yol açarak nekroz, kas iskemisi ve deri hasarına yol açar. Rituksimab ise bu antikorların oluşumunu baskılar (116)(117)(118).…”

Section: D-dermatomiyozitunclassified

Dermatolojide Rituksimab Kullanımı

2014

Dermatoz

View full text Add to dashboard Cite

“…One case demonstrated remission of both skin and muscle disease for over 4 years [97]. A series of three patients with adequate control of muscle disease on other agents utilized rituximab specifically for worsening cutaneous disease [98]. All three patients had improved cutaneous DM following rituximab, with the heliotrope eruption and violaceous poikiloderma being the cutaneous changes demonstrating the best response.…”

Section: Rituximabmentioning

confidence: 99%